Advanced in Pseudomyxoma Peritonei

Dr. Jamie N. Bakkum-Gamez

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
200 1st St Sw, 
Rochester, MN 
Accepting New Patients
Offers Telehealth
Advanced in Pseudomyxoma Peritonei
200 1st St Sw, 
Rochester, MN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jamie Bakkum-Gamez is a Gynecologic Oncologist and an Oncologist in Rochester, Minnesota. Dr. Bakkum-Gamez is rated as an Advanced provider by MediFind in the treatment of Pseudomyxoma Peritonei. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Vulvar Cancer, Hysterectomy, and Oophorectomy. Dr. Bakkum-Gamez is currently accepting new patients.

Her clinical research consists of co-authoring 177 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in MN
Hospital Affiliations
Mayo Clinic Hospital Rochester
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthPartners
  • POS
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

MAYO CLINIC
200 1st St Sw, Rochester, MN 55905

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial Cancer
Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Procedure, Drug, Biological, Other
Study Phase: Phase 1
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 05, 2025
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
WISP (Women Choosing Surgical Prevention)
WISP (Women Choosing Surgical Prevention)
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Other, Procedure
Study Phase: Not Applicable
Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Enrollment Status: Active_not_recruiting
Publish Date: May 03, 2024
Intervention Type: Other
Study Phase: Not Applicable
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
View 6 Less Clinical Trials

177 Total Publications

Epithelial Abnormalities in the High-Risk Fallopian Tube of a Rare TP53/BRCA2 Li-Fraumeni Syndrome Patient With Multiple Tumors.
Epithelial Abnormalities in the High-Risk Fallopian Tube of a Rare TP53/BRCA2 Li-Fraumeni Syndrome Patient With Multiple Tumors.
Journal: JCO precision oncology
Published: June 24, 2025
Similar Doctors
Distinguished in Pseudomyxoma Peritonei
Dr. Robert Mc Williams
Hematology | Oncology
Distinguished in Pseudomyxoma Peritonei
Dr. Robert Mc Williams
Hematology | Oncology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.1 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Mc Williams is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Mc Williams is rated as a Distinguished provider by MediFind in the treatment of Pseudomyxoma Peritonei. His top areas of expertise are Familial Pancreatic Cancer, Pancreatic Cancer, Pseudomyxoma Peritonei, and Melanoma.

Advanced in Pseudomyxoma Peritonei
Dr. Scott Okuno
Oncology | Hematology
Advanced in Pseudomyxoma Peritonei
Dr. Scott Okuno
Oncology | Hematology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.1 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Okuno is an Oncologist and a Hematologist in Rochester, Minnesota. Dr. Okuno is rated as an Elite provider by MediFind in the treatment of Pseudomyxoma Peritonei. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Myxoid Liposarcoma, and Alveolar Soft Part Sarcoma.

Advanced in Pseudomyxoma Peritonei
Dr. Gretchen E. Glaser
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Advanced in Pseudomyxoma Peritonei
Dr. Gretchen E. Glaser
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.1 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Gretchen Glaser is a Gynecologic Oncologist and an Oncologist in Rochester, Minnesota. Dr. Glaser is rated as a Distinguished provider by MediFind in the treatment of Pseudomyxoma Peritonei. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Endometrial Stromal Sarcoma, Hysterectomy, and Lymphadenectomy. Dr. Glaser is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bakkum-Gamez's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 11 Advanced Conditions
View All 37 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile